Increased plasma soluble Met (sMet) levels are associated with lower overall survival in NSCLC patients [53], supporting the results of other studies which showed that MET overexpression and amplification are associated with poor prognosis in NSCLC patients [54–57]. This evidence concerns the gene MET and non-small cell lung carcinoma.